{"seq": 1, "variant": "treatment", "cmd": "pm --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm - PubMed CLI tools for AI agents\n\nUsage: pm <command> [OPTIONS]\n\nRecommended workflow:\n  pm collect     Search + fetch + parse in one command (RECOMMENDED)\n  pm filter      Filter JSONL articles by year, journal, author, etc.\n\nAll commands:\n  collect     Search + fetch + parse in one command (RECOMMENDED)\n  search      Search PubMed, return PMIDs\n  fetch       Fetch PubMed XML by PMIDs\n  parse       Parse PubMed XML to JSONL\n  filter      Filter JSONL articles by field patterns\n  cite        Fetch CSL-JSON citations\n  download    Download full-text PDFs\n  diff        Compare two JSONL files by PMID\n  audit       View audit trail and PRISMA report\n  init        Initialize audit trail and cache (.pm/)\n\nExamples:\n  pm collect \"CRISPR cancer\" --max 100 > results.jsonl\n  pm filter --year 2024 --has-abstract < results.jsonl\n\nTip: save results to a file so you can reuse them without re-searching:\n  pm collect \"my query\" > results.jsonl\n  pm filter --year 2024 < results.jsonl\n  pm filter --has-doi < results.jsonl\n\nUse 'pm <command> --help' for command-specific help.\n", "stderr": "", "elapsed_s": 0.31, "ts": 1771594445.5725276}
{"seq": 2, "variant": "treatment", "cmd": "pm collect --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm collect - Collect PubMed articles (search + fetch + parse \u2192 JSONL)\n\nUsage: pm collect [OPTIONS] \"search query\"\n\nOptions:\n  --max N         Maximum results (default: 100)\n  -v, --verbose   Show progress on stderr\n  -h, --help      Show this help message\n\nOutput:\n  JSONL to stdout (one article per line)\n\nExamples:\n  pm collect \"CRISPR cancer therapy\" --max 100 > results.jsonl\n  pm collect --max 50 \"machine learning diagnosis\" > results.jsonl\n\nFor advanced filtering, use the full pipeline:\n  pm search \"query\" | pm fetch | pm parse | pm filter --year 2024\n", "stderr": "", "elapsed_s": 0.326, "ts": 1771594454.6016433}
{"seq": 3, "variant": "treatment", "cmd": "pm filter --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm filter - Filter JSONL articles by field patterns\n\nUsage: pm parse | pm filter [OPTIONS]\n       cat articles.jsonl | pm filter [OPTIONS]\n\nFilter Options:\n  --year PATTERN      Year filter (exact, range, or open-ended)\n                      Examples: 2024, 2020-2024, 2020-, -2024\n  --journal PATTERN   Journal contains PATTERN (case-insensitive)\n  --journal-exact STR Journal equals STR exactly\n  --author PATTERN    Any author contains PATTERN (case-insensitive)\n  --has-abstract      Article has non-empty abstract\n  --has-doi           Article has DOI\n\nGeneral Options:\n  -v, --verbose       Show filter stats on stderr\n  -h, --help          Show this help\n\nExamples:\n  pm filter --year 2020- --journal nature --has-abstract\n  pm filter --author smith\n  pm filter --year 2020-2024\n\nNotes:\n  - Multiple filters combine with AND logic\n  - Malformed JSON lines are silently skipped\n", "stderr": "", "elapsed_s": 0.287, "ts": 1771594464.9777586}
{"seq": 4, "variant": "treatment", "cmd": "pm search --help", "exit_code": 0, "stdin_lines": 0, "stdout": "pm search - Search PubMed and return PMIDs\n\nUsage: pm search [OPTIONS] \"search query\"\n\nOptions:\n  --max N        Maximum results to return (default: 10000)\n  --refresh      Bypass cache and re-fetch from PubMed\n  -h, --help     Show this help message\n\nOutput:\n  PMIDs to stdout, one per line\n\nTip: for most tasks, use 'pm collect' instead \u2014 it runs search + fetch + parse\nin one command and outputs JSONL directly:\n  pm collect \"CRISPR cancer therapy\" --max 100 > results.jsonl\n\nIf you need raw PMIDs, save them to a file for reuse:\n  pm search \"CRISPR cancer therapy\" --max 100 > pmids.txt\n  cat pmids.txt | pm fetch | pm parse > results.jsonl\n\nQuery syntax:\n  Uses PubMed query syntax. See:\n  https://pubmed.ncbi.nlm.nih.gov/help/#search-tags\n", "stderr": "", "elapsed_s": 0.203, "ts": 1771594481.8120077}
{"seq": 5, "variant": "treatment", "cmd": "pm search FES PET breast cancer --max 200 2", "exit_code": 0, "stdin_lines": 0, "stdout": "2\n", "stderr": "", "elapsed_s": 0.728, "ts": 1771594776.7019472}
{"seq": 6, "variant": "treatment", "cmd": "pm search breast cancer --max 5", "exit_code": 0, "stdin_lines": 0, "stdout": "41717763\n41717547\n41717435\n41717413\n41717404\n", "stderr": "", "elapsed_s": 0.884, "ts": 1771595373.6579778}
{"seq": 7, "variant": "treatment", "cmd": "pm search FES PET lobular breast cancer --max 200", "exit_code": 0, "stdin_lines": 0, "stdout": "41319353\n40976009\n40914389\n40813238\n40761268\n40369385\n40300962\n40067459\n40035673\n39438056\n39385362\n39058489\n38427956\n38365547\n38117098\n38071554\n37239021\n36919879\n36879065\n36243494\n36083216\n35681669\n34545689\n32680923\n32374053\n28604479\n27607175\n25693420\n17515338\n", "stderr": "", "elapsed_s": 0.641, "ts": 1771595384.5321417}
{"seq": 8, "variant": "treatment", "cmd": "pm search fluoroestradiol PET lobular breast --max 200", "exit_code": 0, "stdin_lines": 0, "stdout": "41319353\n40976009\n40813238\n40761268\n40369385\n40035673\n39438056\n39385362\n39058489\n38365547\n38117098\n36919879\n36879065\n36243494\n36083216\n35681669\n34643778\n32680923\n28604479\n27607175\n17515338\n", "stderr": "", "elapsed_s": 0.652, "ts": 1771595393.776857}
{"seq": 9, "variant": "treatment", "cmd": "pm search (FES OR fluoroestradiol OR 18F-FES) AND PET AND (lobular OR ILC) AND breast --max 200", "exit_code": 0, "stdin_lines": 0, "stdout": "41319353\n40976009\n40914389\n40813238\n40761268\n40369385\n40300962\n40067459\n40035673\n39438056\n39385362\n39058489\n38427956\n38365547\n38117098\n38071554\n37239021\n36919879\n36879065\n36243494\n36083216\n35681669\n34643778\n34545689\n32680923\n32374053\n31016232\n28604479\n27607175\n25693420\n17515338\n", "stderr": "", "elapsed_s": 0.708, "ts": 1771595403.0990543}
{"seq": 10, "variant": "treatment", "cmd": "pm search (FES OR fluoroestradiol OR 18F-FES OR estrogen receptor imaging) AND PET AND (lobular OR ILC) AND (breast cancer OR breast carcinoma) --max 300", "exit_code": 0, "stdin_lines": 0, "stdout": "41649854\n41319353\n40976009\n40914389\n40813238\n40761268\n40525019\n40369385\n40300962\n40147847\n40067459\n40035673\n39438056\n39385362\n39058489\n38427956\n38396455\n38365547\n38117098\n38071554\n37500131\n37239021\n36988272\n36919879\n36879065\n36243494\n36083216\n35890071\n35681669\n34829301\n34764233\n34643778\n34545689\n34484361\n33198673\n32683540\n32680923\n32374053\n32328848\n32318957\n31587025\n31342365\n31016232\n30652258\n30191351\n28604479\n28188325\n28057031\n27856207\n27798919\n27607175\n27569020\n26774154\n26663655\n26140849\n25889560\n25693420\n24025919\n23084013\n22359222\n21785049\n20809217\n20565953\n19160365\n18407934\n18098228\n17515338\n12271413\n11197987\n", "stderr": "", "elapsed_s": 0.787, "ts": 1771595413.4384286}
{"seq": 11, "variant": "treatment", "cmd": "pm collect (FES OR fluoroestradiol OR 18F-FES OR estrogen receptor imaging) AND PET AND (lobular OR ILC) AND (breast cancer OR breast carcinoma) --max 300 -v", "exit_code": 0, "stdin_lines": 0, "stdout": "{\"pmid\": \"41649854\", \"title\": \"68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis: Edge Over 18F-FDG PET/CT?\", \"authors\": [\"Mohite Ashish\", \"Luthra Karuna\", \"Pathan Sameer\", \"Malik Amrita\", \"Kesariya Jugal\"], \"journal\": \"Clinical nuclear medicine\", \"year\": \"2026\", \"date\": \"2026-01-30\", \"abstract\": \"FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases. Trivehexin PET targets \u03b1v\u03b26 integrin, which is relatively specific for epithelial cancer cells. We present a case of a 67-year-old woman with recently diagnosed metastatic breast cancer. Trivehexin PET not only showed lesions with a higher target-to-background ratio compared with FDG PET but also depicted additional metastatic sites.\", \"doi\": \"10.1097/RLU.0000000000006178\"}\n{\"pmid\": \"41319353\", \"title\": \"Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.\", \"authors\": [\"Covington Matthew F\", \"Salmon Samantha\", \"Kozlov Andrew\", \"Archibald Zane\", \"Butterfield Regan\", \"Stolk Sophie\", \"Mitchell Sam\", \"Boucher Kenneth\", \"Rosenthal Regina\", \"Porretta Jane\", \"Brownson Kirstyn E\", \"Matsen Cindy\", \"Wei Mei\", \"Buys Saundra\", \"Vaklavas Christos\", \"Chittoria Namita\", \"Buckway Brandon\", \"Meite Angela\", \"Yap Jeffrey\"], \"journal\": \"Clinical breast cancer\", \"year\": \"2026\", \"date\": \"2026-01\", \"abstract\": \"Invasive lobular carcinoma (ILC) often presents diagnostic challenges on conventional imaging, necessitating advanced imaging strategies for accurate staging. [18F]Fluoroestradiol (FES), a PET radiopharmaceutical, targets estrogen receptor-positive (ER+) lesions, which are prevalent in ILC. This study evaluates the utility of FES-PET/CT compared to standard-of-care (SOC) imaging for staging ER+ ILC. This IRB-approved prospective trial (October 2022-October 2024) enrolled adults with histologically confirmed ER+ ILC at a National Cancer Institute-designated Comprehensive C", "stderr": "Searching PubMed: \"(FES OR fluoroestradiol OR 18F-FES OR estrogen receptor imaging) AND PET AND (lobular OR ILC) AND (breast cancer OR breast carcinoma)\" (max 300)...\nFetching batch 1 (69 PMIDs)...\n", "elapsed_s": 1.351, "ts": 1771595429.1051326}
{"seq": 12, "variant": "treatment", "cmd": "pm filter --year 2020- --has-abstract -v", "exit_code": 0, "stdin_lines": 69, "stdout": "{\"pmid\": \"41649854\", \"title\": \"68Ga Trivehexin PET/CT in a Breast Carcinoma Patient With Distant Metastasis: Edge Over 18F-FDG PET/CT?\", \"authors\": [\"Mohite Ashish\", \"Luthra Karuna\", \"Pathan Sameer\", \"Malik Amrita\", \"Kesariya Jugal\"], \"journal\": \"Clinical nuclear medicine\", \"year\": \"2026\", \"date\": \"2026-01-30\", \"abstract\": \"FDG PET CT has limitations in breast cancer due to its low tracer uptake in Grade 1 and 2 tumors, estrogen receptor positivity, lobular histology, and osteoblastic skeletal metastases. Trivehexin PET targets \u03b1v\u03b26 integrin, which is relatively specific for epithelial cancer cells. We present a case of a 67-year-old woman with recently diagnosed metastatic breast cancer. Trivehexin PET not only showed lesions with a higher target-to-background ratio compared with FDG PET but also depicted additional metastatic sites.\", \"doi\": \"10.1097/RLU.0000000000006178\"}\n{\"pmid\": \"41319353\", \"title\": \"Staging Invasive Lobular Carcinoma: A Prospective Study on the Efficacy of 18F-Fluoroestradiol (FES)-PET/CT.\", \"authors\": [\"Covington Matthew F\", \"Salmon Samantha\", \"Kozlov Andrew\", \"Archibald Zane\", \"Butterfield Regan\", \"Stolk Sophie\", \"Mitchell Sam\", \"Boucher Kenneth\", \"Rosenthal Regina\", \"Porretta Jane\", \"Brownson Kirstyn E\", \"Matsen Cindy\", \"Wei Mei\", \"Buys Saundra\", \"Vaklavas Christos\", \"Chittoria Namita\", \"Buckway Brandon\", \"Meite Angela\", \"Yap Jeffrey\"], \"journal\": \"Clinical breast cancer\", \"year\": \"2026\", \"date\": \"2026-01\", \"abstract\": \"Invasive lobular carcinoma (ILC) often presents diagnostic challenges on conventional imaging, necessitating advanced imaging strategies for accurate staging. [18F]Fluoroestradiol (FES), a PET radiopharmaceutical, targets estrogen receptor-positive (ER+) lesions, which are prevalent in ILC. This study evaluates the utility of FES-PET/CT compared to standard-of-care (SOC) imaging for staging ER+ ILC. This IRB-approved prospective trial (October 2022-October 2024) enrolled adults with histologically confirmed ER+ ILC at a National Cancer Institute-designated Comprehensive C", "stderr": "39 articles passed filters\n", "elapsed_s": 0.189, "ts": 1771595450.428425}
